PI3K signaling pathway in colorectal cancer

doi:10.3760/cma.j.issn.1673422X.2016.08.018

Abstract

Abstract: Since the early symptoms are very hidden, most of patients with colorectal cancer (CRC) have occurred metastasis when diagnosed. Recently, chemotherapy combined with targeted therapy is the major therapeutic strategy for metastatic CRC and the high frequency activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway has been validated sharing a close relationship with the development of CRC, contributing important values for the diagnosis and therapy of CRC.

Key words: Colorectal neoplasms, 1-Phosphatidylinositol 3-kinase, Signal transduction, Drug therapy

Wang Hao, Zhang Qingling. PI3K signaling pathway in colorectal cancer[J]. Journal of International Oncology, 2016, 43(8): 631-633.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting［J］. Nat Rev Cancer, 2015, 15(1): 7-24. DOI: 10.1038/nrc3860. ［3］ Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer［J］. Int J Cancer, 2007, 121(8): 1771-1778. DOI: 10.1002/ijc.22890. ［4］ Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage Ⅲ colon cancer intergroup trial［J］. J Natl Cancer Inst, 2013, 105(23): 1789-1798. DOI: 10.1093/jnci/djt298. ［5］ Kaur J, Sanyal SN. PI3kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac［J］. Tumour Biol, 2010, 31(6): 623-631. DOI: 10.1007/s13277-010-0078-9. ［6］ Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival［J］. N Engl J Med, 2012, 367(17): 1596-1606. DOI: 10.1056/NEJMoa1207756. ［7］ Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal antiinflammatory drug therapy in colorectal cancer［J］. J Clin Oncol, 2013, 31(34): 4297-4305. DOI: 10.1200/JCO.2013.50.0322. ［8］ Van Cutsem E, Khne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colo-rectal cancer: updated analysis of overall survival according to tumor K-RAS and BRAF mutation status［J］. J Clin Oncol, 2011, 29(15): 2011-2019. DOI: 10.1200/JCO.2010.33.5091. ［9］ SartoreBianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies［J］. Cancer Res, 2009, 69(5): 1851-1857. DOI: 10.1158/0008-5472.CAN-08-2466. ［10］ Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents［J］. Clin Cancer Res, 2013, 19(3): 657-667. DOI: 10.1158/1078-0432.CCR-11-1446. ［11］ Zhu YF, Yu BH, Li DL, et al. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases［J］. World J Gastroenterol, 2012, 18(28): 3745-3751. DOI: 10.3748/wjg.v18.i28.3745. ［12］ Wang G, Wang F, Ding W, et al. April induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway［J］. PLoS One, 2013, 8(1): e55298. DOI: 10.1371/journal.pone.0055298. ［13］ Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers［J］. J Surg Oncol, 2015, 111(7): 905-910. DOI: 10.1002/jso.23895. ［14］ Bendell JC, Rodon J, Burris HA, et al. Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors［J］. J Clin Oncol, 2012, 30(3): 282-290. DOI: 10.1200/JCO.2011.36.1360. ［15］ Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2012, 18(15): 4173-4182. DOI: 10.1158/1078-0432.CCR-12-0714. ［16］ Sarker D, Ang JE, Baird R, et al. Firstinhuman phase I study of pictilisib (GDC0941), a potent panclass I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2015, 21(1): 77-86. DOI: 10.1158/1078-0432.CCR-14-0947. ［17］ Roper J, Richardson MP, Wang WV, et al. The dual PI3K/mTOR inhibitor NVPBEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wildtype colorectal cancer［J］. PLoS One, 2011, 6(9): e25132. DOI: 10.1371/journal.pone.0025132. ［18］ Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patientderived xenografts of RASmutant colorectal carcinomas［J］. Clin Cancer Res, 2012, 18(9): 2515-2525. ［19］ Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer［J］. J Clin Oncol, 2010, 28(6): 1075-1083. DOI: 10.1200/JCO.2009.25.3641. ［20］ Yap TA, Yan L, Patnaik A, et al. Firstinman clinical trial of the oral panAKT inhibitor MK2206 in patients with advanced solid tumors［J］. J Clin Oncol, 2011, 29(35): 4688-4695. DOI: 10.1200/JCO.2011.35.5263. ［21］ Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition［J］. Sci Signal, 2009, 2(67): pe24. DOI: 10.1126/scisignal.267pe24. ［22］ Wolpin BM, Ng K, Zhu AX, et al. Multicenter phase Ⅱ study of tivozanib (AV951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer［J］. Oncologist, 2013, 18(4): 377-378. DOI: 10.1634/theoncologist.2012-0378. ［23］ Spindler KL, Sorensen MM, Pallisgaard N, et al. Phase Ⅱ trial of temsirolimus alone and in combination with irinotecan for K-RAS mutant metastatic colorectal cancer: outcome and results of K-RAS mutational analysis in plasma［J］. Acta Oncol, 2013, 52(5): 963970. DOI: 10.3109/0284186X.2013.776175. ［24］ Altomare I, Hurwitz H. Everolimus in colorectal cancer［J］. Expert Opin Pharmacother, 2013, 14(4): 505-513. DOI: 10.1517/14656566.2013.770473. ［25］ Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dualtargeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer［J］. Clin Cancer Res, 2012, 18(8): 2316-2325. DOI: 10.1158/1078-0432.CCR-11-2381.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.